| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ea1fff38e27d2aa34504ab65f60e7631
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b5b9f9cd8f41ddd9b8e5bc26a4d68518
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_de53344c8f931a1c5a14f660a0b7d1a7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a8e20137e10efebd66f7b326dc42151 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/E02D2600-20 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/E02D17-205 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-245 |
| filingDate |
2003-02-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_16b4b552be4221feef22bbd3736945e9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_89eab0df0dcf181a9f6c05506bfdbf33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3d214ef55f1d7739374660ce3502b9c9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3c19cdc72cb468350a9b99334ffb128a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_33779f8ce83b986b76ca6aeb7b49178c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_127d5edf1a8b921f9dd70d7037a260c2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fcdb844d9ded1813f3645ebddd2f1d9d |
| publicationDate |
2004-08-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20040074190-A |
| titleOfInvention |
Therapeutic dna vaccine for tuberculosis and pharmaceutical composition containing the same |
| abstract |
The present invention relates to a tuberculosis DNA vaccine comprising tuberculosis antigen DNA and a pharmaceutical composition for treating tuberculosis containing the DNA vaccine as an active ingredient, and more specifically, the signal of herpes simplex virus type I glycoprotein D (gD). It relates to a tuberculosis DNA vaccine comprising a sequence and Ag85A gene, and a pharmaceutical composition for treating tuberculosis containing the DNA vaccine and tuberculosis therapeutic agent as an active ingredient. The DNA vaccine of the present invention can be useful for the treatment of tuberculosis because it can reduce the possibility of tuberculosis recurrence due to continuous induction of immune response and can reduce the treatment period when combined with conventional chemotherapy. have. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102268446-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102268446-A |
| priorityDate |
2003-02-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |